土耳其心力衰竭患者的并发症负担
Yüksel Çavuşoğlu1, Selda Murat1, Anıl Şahin2
1Department of Cardiology, Faculty of Medicine, Eskişehir Osmangazi University, Eskişehir, Turkiye.
Turkish journal of medical sciences
|December 30, 2024
概括
在土耳其的心力衰竭患者经常有多种并发症,高血压和动脉样性心血管疾病是最常见的. 同病率因性别而异,并且随着年龄的增长而显著增加.
科学领域:
- 心脏病学 心脏病学
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 心力衰竭 (HF) 是与众多并发症相关的重大健康问题.
- 这些并发症会对患者的治疗结果产生负面影响,并增加医疗保健成本.
- 了解高风的并发症模式对于有效管理至关重要.
研究的目的:
- 确定土耳其心力衰竭患者的并发症的频率和负担.
- 分析HF患者的并发症和人口因素之间的关系.
- 提供对该地区HF患者综合健康状况的见解.
主要方法:
- 利用来自土耳其 (2016-2022) 的全国电子健康数据,覆盖超过8500万个人.
- 鉴定了心力衰竭患者,并使用ICD-10代码分析了他们的并发症.
- 对不同年龄组,性别和社会经济地位的共患病率进行了评估.
主要成果:
- 超过270万HF患者被确定,高血压 (97.6%) 和动脉样性心血管疾病 (84.9%) 是最常见的并发症.
- 超过90%的HF患者至少有两种并发症.
- 在性别之间观察到并发症患病率的显著差异,并随着年龄的增长而增加并发症的数量.
结论:
- 高血压,动脉样性心血管疾病,血脂不良,糖尿病,慢性肺炎,贫血和心房动是土耳其HF患者中最常见的并发症.
- 多种并发症的高患病率强调了高温管理的复杂性.
- 年龄和性别是影响心力衰竭并发症概况的关键人口统计因素.
相关概念视频
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:23Imbalances in Cardiac Output
1.1K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
1.1K
01:22Heart Failure Drugs: β-Blockers
257
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
257
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.6K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.6K
01:22Heart Failure Drugs: Diuretics
273
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
273
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
299
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
299